Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20006074 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL15335166 | 0.68 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL15334892 | 0.66 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL22686382 | 0.66 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL18363119 | 0.65 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL22015932 | 0.64 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL9918122 | 0.63 | APEX1 (0.46) | ALDH1A1 | |
| Nibrozetone SCHEMBL2249018 | 0.62 | NLRP3 (0.47) | ALDH1A1 | |
| SCHEMBL8149192 | 0.59 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL11581015 | 0.59 | KDM4E (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233524-A1 | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE | EPICENTRX, INC. (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233524-A1 | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE | HBZ, OPRK1, ANXA3 | ALDH1A1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.